reports
AmpliPhi Biosciences’ CEO to Moderate Panel Discussion at Upcoming A...
SAN DIEGO--(BUSINESS WIRE)-- AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that CEO Paul C. Grint, M.D., will moderate a panel titled, “Advances Against Rare and Resistant Pathogens” at the Anti-Infectives Rx Conference to be held on September 19, 2017 at the Harvard Medical School in Boston. The Anti-Infectives Rx Conference is a networking forum featuring ...
AmpliPhi Biosciences Announces First Intravenous Treatment of a Patien...
SAN DIEGO--(BUSINESS WIRE)-- AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces the first-in-human intravenous administration of AmpliPhi’s drug candidate AB-SA01. AmpliPhi supplied AB-SA01 to a major hospital in Australia for a patient suffering from a life-threatening Staphylococcus aureus (S. aureus) infection of the heart (endocarditis). AB-SA01 was administered intraveno...
AmpliPhi Biosciences Announces Receipt of $2.0 Million R&D Tax Incenti...
SAN DIEGO--(BUSINESS WIRE)-- AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that it has received a Research and Development (R&D) Tax Incentive cash rebate of USD $2.0 million from the Australian Tax Office based on the Company’s R&D spending in Australia during 2016. The Company will recognize the $2.0 million payment received in its financial statements for the quarter ...
AmpliPhi Biosciences to Present at Rodman & Renshaw 19th Annual Global...
SAN DIEGO--(BUSINESS WIRE)-- AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that Paul C. Grint, M.D., Chief Executive Officer, will present a company overview at the Rodman & Renshaw 19th Annual Global Investment Conference on Monday, Sept. 11. “We are developing our proprietary bacteriophage technology using expanded access regulatory guidelines established by t...
AmpliPhi Biosciences Announces Publication of Bacteriophage Case Study...
SAN DIEGO--(BUSINESS WIRE)-- AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces publication of a case study highlighting the successful treatment of a critically ill patient with a multidrug-resistant (MDR) Acinetobacter baumannii (A. baumannii) infection. The manuscript, “Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a ...
AmpliPhi Biosciences Reports Second Quarter 2017 Financial Results and...
SAN DIEGO--(BUSINESS WIRE)-- AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces financial results for the three and six months ended June 30, 2017 and business highlights. “The establishment of the Global Antimicrobial Resistance (AMR) Collaboration Hub at the recent G20 summit in July underscores the importance of the AMR issue for public health,” said Paul C. Grint, M.D., CEO of AmpliPhi Biosciences. “I am ...
AmpliPhi Biosciences to Hold 2017 Second Quarter and Business Update C...
SAN DIEGO--(BUSINESS WIRE)-- AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces that management will hold a business update conference call on Monday, August 14, 2017 beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). Live Ca...
AmpliPhi Biosciences to Present at Bacteriophage Therapy Workshop Spon...
SAN DIEGO--(BUSINESS WIRE)-- AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces that it has been invited to present at a workshop entitled “Bacteriophage Therapy: Scientific and Regulatory Issues” being held July 10-11, 2017 in Rockville, MD. This workshop is being organized by the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research and the National Institutes of H...
AmpliPhi Biosciences Announces Presentation and Panel Participation at...
SAN DIEGO--(BUSINESS WIRE)-- AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces that CEO Dr. Paul Grint will present a company overview on June 21, 2017, at 2:15 p.m. Pacific time at the 2017 BIO International Convention. Dr. Grint will also participate in the panel session, “Adding Tools to the Toolbox: New Technologies to Overcome AMR Mechanisms,” on the same day beginning at 4:15 p.m. Pacific tim...
AmpliPhi Biosciences Appoints Paul C. Grint, M.D. as Chief Executive O...
SAN DIEGO--(BUSINESS WIRE)-- AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces the appointment of Paul C. Grint, M.D. as Chief Executive Officer, effective immediately. Dr. Grint has served on the Company’s board of directors since November 2015 and has more than two decades of executive leadership experience in biologics and small molecule development, including the successful development and commerciali...
AmpliPhi Biosciences to Present at 7th Annual LD Micro Invitational Co...
SAN DIEGO--(BUSINESS WIRE)-- AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces that CEO M. Scott Salka will present a company overview at the 7th Annual LD Micro Invitational Conference at the Luxe Hotel in Los Angeles on Tuesday, June 6, 2017, at 4:30 p.m. Pacific Time. “We look forward to discussing our new strategic emphasis on utilizing our proprietary bacteriophage technology to devel...
AmpliPhi Biosciences Reports First Quarter 2017 Financial Results and ...
SAN DIEGO--(BUSINESS WIRE)-- AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces financial results for the quarter ended March 31, 2017 and provides business highlights. “We are enthusiastic about our new strategic emphasis on utilizing proprietary bacteriophage technology to develop personalized precision phage therapies for patients who suffer from serious or life-threatening multidrug-resistant (MDR) bacter...
AmpliPhi Biosciences to Hold Business Update Conference Call on May 15
SAN DIEGO--(BUSINESS WIRE)-- AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announces that management will hold a business update conference call on Monday, May 15, 2017 beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). Live Call: U.S. 877-866-5534 ...
AmpliPhi Biosciences Announces Closing of Public Offering
SAN DIEGO--(BUSINESS WIRE)-- AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a biotechnology company focused on the development of therapies for drug-resistant bacterial infections using bacteriophage technology, today announced the closing of its previously announced underwritten public offering. Total proceeds to AmpliPhi from the offering were approximately $9.1 million, after deducting the underwriting discount and commissions and estimated offering expenses payable by AmpliPhi, and excluding any proceeds that may be received u...
AmpliPhi Biosciences Announces Pricing of $10.4 Million Underwritten P...
SAN DIEGO--(BUSINESS WIRE)-- AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a biotechnology company focused on the development of therapies for drug-resistant bacterial infections using bacteriophage technology, today announced the pricing of an underwritten public offering of 6,956,522 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), and common warrants to purchase up to an aggregate of 6,956,522 shares of common stock. Each share of common stock and, as applicable, pre-funded warrant ...
AmpliPhi Biosciences Announces a New Strategic Emphasis on Personalize...
SAN DIEGO--(BUSINESS WIRE)-- AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the field of bacteriophage technology, announces a new strategic emphasis on precisely targeted and personalized medicines designed to address the surging global threat posed by bacteria that have become resistant to antibiotics. Under existing compassionate-use guidelines, AmpliPhi expects to provide personalized phage therapies to patients suffering from severe, multidrug-resistant (MDR) infections who have failed prior therapies. In addition...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.